Chiba Toshimi, Kudara Norihiko, Sato Masaki, Chishima Raita, Abiko Yukito, Inomata Masaaki, Orii Seishi, Suzuki Kazuyuki
First Department of Internal Medicine, Iwate Medical University, Morioka, Iwate, Japan.
Hepatogastroenterology. 2005 Sep-Oct;52(65):1416-20.
BACKGROUND/AIMS: Calcium polycarbophil improves abdominal symptoms in patients with irritable bowel syndrome (IBS). We examined colonic transit times in IBS patients both before and after administration of calcium polycarbophil, and clarified the correlations among colonic transit, bowel movements, stool form and abdominal pain.
A total of 26 IBS patients (14 diarrhea-predominant type, 12 constipation-predominant type) with a median age of 51 yr were enrolled. Before administration of calcium polycarbophil, mean colonic transit times were calculated from the number of radiopaque markers in the colon. Bowel movements, the stool form scale score and abdominal pain were also measured. After oral administration of calcium polycarbophil for 8 weeks, the transit times were again measured.
In diarrhea type, the mean colonic transit time increased, bowel movements decreased in frequency, the stool form scale score decreased, and the abdominal pain appeared to be diminished after treatment (p<0.05). In constipation type, mean colonic transit time decreased, bowel movements increased in frequency, the stool form scale score increased, the abdominal pain appeared to be diminished after treatment (p<0.05). Colonic transit times were highly correlated with stool form or bowel movements. Stool form was also highly correlated with bowel movements before and after treatment. Abdominal pain was significantly correlated with colonic transit before treatment.
Calcium polycarbophil is useful in improving colonic transit, bowel movements, stool form and abdominal pain in both types of IBS. Improvement in colonic transit might relieve abdominal pain in IBS patients.
背景/目的：聚卡波非钙可改善肠易激综合征（IBS）患者的腹部症状。我们检测了聚卡波非钙给药前后IBS患者的结肠转运时间，并阐明了结肠转运、排便、粪便形态与腹痛之间的相关性。
共纳入26例IBS患者（年龄中位数51岁），其中腹泻型14例，便秘型12例。在给予聚卡波非钙之前，根据结肠内不透X线标志物的数量计算平均结肠转运时间。同时测量排便情况、粪便形态量表评分及腹痛情况。口服聚卡波非钙8周后，再次测量转运时间。
腹泻型患者治疗后平均结肠转运时间延长，排便频率降低，粪便形态量表评分降低，腹痛似乎减轻（p<0.05）。便秘型患者治疗后平均结肠转运时间缩短，排便频率增加，粪便形态量表评分增加，腹痛似乎减轻（p<0.05）。结肠转运时间与粪便形态或排便情况高度相关。治疗前后粪便形态与排便情况也高度相关。治疗前腹痛与结肠转运显著相关。
聚卡波非钙对改善两种类型IBS的结肠转运、排便、粪便形态及腹痛均有效。结肠转运的改善可能缓解IBS患者的腹痛。
